Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Loteprednol Etabonate

FDA-approved product (suspension/drops, ophthalmic), marketed as Alrex, Eysuvis, Inveltys and 3 more.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Loteprednol Etabonate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Allergic conjunctivitis
  • Anterior uveitis
  • Dry eye syndrome
  • Eye inflammation
  • Inflammation

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Corticosteroids, plain
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA. It was surfaced computationally for further investigation; it is not an established treatment for this infection.

AI-predicted activity

AI prediction · nothing measured
  • MRSA53.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli39.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae23.5% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis34.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Loteprednol Etabonate in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-6.1 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-6.4 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.0 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.0 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Loteprednol Etabonate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Loteprednol Etabonate Ophthalmic Ointment vs. Vehicle in the Treatment of Inflammation Following Cataract Surgery

    NCT00645671 · start 2008-03

    Registered record
    Registry ID
    NCT00645671
    Conditions
    Ocular Inflammation
    Interventions
    0.5% Loteprednol Etabonate Ophthalmic Ointment; Vehicle of Loteprednol Etabonate Ophthalmic Ointment
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2008-03
    Completion
    2009-03
    Enrolment
    400

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOcular Inflammation
    Intervention0.5% Loteprednol Etabonate Ophthalmic Ointment; Vehicle of Loteprednol Etabonate Ophthalmic Ointment
    PhasePhase 3
    Registry statusCompleted

  • Zylet vs TobraDex in Blepharokeratoconjunctivitis

    NCT00447577 · start 2007-01

    Registered record
    Registry ID
    NCT00447577
    Conditions
    Blepharokeratoconjunctivitis
    Interventions
    Loteprednol etabonate and tobramycin ophthalmic suspension; Tobramycin and dexamethasone ophthalmic suspension
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2007-01
    Completion
    2007-06
    Enrolment
    276

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBlepharokeratoconjunctivitis
    InterventionLoteprednol etabonate and tobramycin ophthalmic suspension; Tobramycin and dexamethasone ophthalmic suspension
    PhasePhase 4
    Registry statusCompleted

  • Multicenter, Randomized, Controlled Study of the Effect of Lotemax on Initiation of Dry Eye Treatment With Restasis

    NCT00407043 · start 2006-11

    Registered record
    Registry ID
    NCT00407043
    Conditions
    Dry Eye Disease; Keratoconjunctivitis Sicca
    Interventions
    Lotemax; Restasis
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2006-11
    Completion
    2007-09
    Enrolment
    5

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDry Eye Disease; Keratoconjunctivitis Sicca
    InterventionLotemax; Restasis
    PhasePhase 4
    Registry statusCompleted

  • Intraocular Pressure With Loteprednol and Dexamethasone

    NCT00781300 · start 2006-03

    Registered record
    Registry ID
    NCT00781300
    Conditions
    Glaucoma, Open-Angle; Ocular Hypertension
    Interventions
    Loteprednol Etabonate 0.5%; Dexamethasone 0.1%
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2006-03
    Completion
    2007-02
    Enrolment
    35

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGlaucoma, Open-Angle; Ocular Hypertension
    InterventionLoteprednol Etabonate 0.5%; Dexamethasone 0.1%
    PhasePhase 4
    Registry statusCompleted

  • Comparison of Acular LS With Lotemax to Prevent Inflammation After Cataract Surgery and Intraocular Lens Implantation

    NCT00366691 · start 2006-02

    Registered record
    Registry ID
    NCT00366691
    Conditions
    Cataract Extraction
    Interventions
    Acular LS; Lotemax
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2006-02
    Completion
    2007-09
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCataract Extraction
    InterventionAcular LS; Lotemax
    PhasePhase 4
    Registry statusCompleted